Table 2. Univariate Cox Analysis of Predictors of Early Mortality.

Variable	Deaths(total = 14)n (%)	Survivors(total = 213)n (%)	Hazard ratio(95% CI)	p
White race	7 (50)	100 (47)	1.13 (0.39–3.22)	0.82
Age >40	6 (43)	68 (32)	1.52 (0.53–4.35)	0.43
Male sex	12 (86)	150 (70)	2.53 (0.56–11.5)	0.23
Men who have sex with men	4 (29)	62 (29)	1.07 (0.33–3.48)	0.90
Alcohol abuse	3 (22)	51 (24)	0.97 (0.26–3.53)	0.96
Intravenous drug use	1 (7)	11 (5)	1.31 (0.18–9.53)	0.79
Other illicit drugs use	3 (22)	61 (29)	0.73 (0.20–2.62)	0.63
School education >8 years	6 (43)	82 (39)	1.19 (0.41–3.40)	0.75
Monthly income ≤ U$500.00	9 (64)	152 (71)	0.87 (0.27–2.78)	0.82
Time since HIV diagnosis (for each month)a	3.5	17.0	1.00 (0.99–1.01)	0.97
HAART naïve	8 (57)	129 (61)	0.99 (0.30–3.26)	0.99
TB as criteria for AIDS diagnosis	8 (57)	89 (42)	2.26 (0.66–7.74)	0.20
Disseminated TB	9 (64)	67 (32)	4.02 (1.37–11.8)	0.01
Weight loss >10%	7 (50)	146 (69)	0.58 (0.18–1.88)	0.36
Positive smear	11 (79)	135 (63)	3.13 (0.67–14.7)	0.15
Hemoglobin ≥10g%	3 (21)	110 (52)	0.23 (0.06–0.81)	0.02
Serum albumin ≥3g%b	3 (21)	92 (51)	0.26 (0.07–0.96)	0.04
TB symptoms for >120 days	6 (43)	66 (31)	1.65 (0.57–4.8)	0.36
CD4 cell count >100 cells/mm3c	3 (21)	126 (56)	0.27 (0.08–0.96)	0.04
Unknown CD4 cell count	7 (50)	25 (12)	6.80 (2.33–20.0)	<0.001
Viral load (for each log/mL)d	5.22	4.89	9.40 (1.29–68.7)	0.03
Resistance to one anti-TB drug	0	23 (11)	Undefined	0.07
Multi-drug resistance	0	8 (4)	Undefined	0.30
Susceptible TB treated with rifampin	11 (79)	174 (82)	0.85 (0.23–3.07)	0.80
IRIS	2 (14)	12 (6)	2.73 (0.61–12.0)	0.19
HAARTe	7 (50)	186 (87)	0.23 (0.07–0.76)	0.01

TB = tuberculosis; CI = confidence interval; HAART = highly active anti-retroviral therapy; IRIS = immune reconstitution inflammatory syndrome;

^amedian;

^bmissing data for 37 (16%) patients;

^cmissing data for 32 (14%) patients;

^dmissing data for 50 (22%) patients;

^etime-dependent variable.